Search

Your search keyword '"Waters, David D."' showing total 492 results
Start Over Author "Waters, David D." Language english
492 results on '"Waters, David D."'

1. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Author

Tardif, Jean-Claude, Bouabdallaoui, Nadia, L'Allier, Philippe L, Gaudet, Daniel, Shah, Binita, Pillinger, Michael H, Lopez-Sendon, Jose, da Luz, Protasio, Verret, Lucie, Audet, Sylvia, Dupuis, Jocelyn, Denault, André, Pelletier, Martin, Tessier, Philippe A, Samson, Sarah, Fortin, Denis, Tardif, Jean-Daniel, Busseuil, David, Goulet, Elisabeth, Lacoste, Chantal, Dubois, Anick, Joshi, Avni Y, Waters, David D, Hsue, Priscilla, Lepor, Norman E, Lesage, Frédéric, Sainturet, Nicolas, Roy-Clavel, Eve, Bassevitch, Zohar, Orfanos, Andreas, Stamatescu, Gabriela, Grégoire, Jean C, Busque, Lambert, Lavallée, Christian, Hétu, Pierre-Olivier, Paquette, Jean-Sébastien, Deftereos, Spyridon G, Levesque, Sylvie, Cossette, Mariève, Nozza, Anna, Chabot-Blanchet, Malorie, Dubé, Marie-Pierre, Guertin, Marie-Claude, and Boivin, Guy

Published
2021
Full Text
View/download PDF

6. Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).

Author

Roubille, François, Bouabdallaoui, Nadia, Kouz, Simon, Waters, David D., Diaz, Rafael, Maggioni, Aldo P., Pinto, Fausto J., Grégoire, Jean C., Gamra, Habib, Kiwan, Ghassan S., Berry, Colin, López-Sendón, José, Koenig, Wolfgang, Delorme, Laurent, Elbaz, Meyer, Coste, Pierre, Provencher, Mylène, Bassevitch, Zohar, Blondeau, Lucie, and L’Allier, Philippe L.

Subjects
TYPE 2 diabetes, MYOCARDIAL infarction, COLCHICINE, CORONARY disease
Abstract

OBJECTIVE: The cardiovascular benefits of low-dose colchicine have been demonstrated in patients with coronary disease. Its effects were evaluated in this prespecified analysis in patients with type 2 diabetes (T2D) from the Colchicine Cardiovascular Outcomes Trial (COLCOT). RESEARCH DESIGN AND METHODS: COLCOT was a randomized, double-blinded trial of colchicine, 0.5 mg daily, versus placebo initiated within 30 days after a myocardial infarction. RESULTS: There were 959 patients with T2D enrolled and monitored for a median of 22.6 months. A primary end point event occurred in 8.7% of patients in the colchicine group and in 13.1% in the placebo group (hazard ratio 0.65; 95% CI 0.44–0.96; P = 0.03). Nausea was reported in 2.7% and 0.8% in the study groups (P = 0.03), and pneumonia occurred in 2.4% and 0.4% (P = 0.008). CONCLUSIONS: Among patients with T2D and a recent myocardial infarction, colchicine, 0.5 mg daily, leads to a large reduction of cardiovascular events. These results support the conduct of the COLCOT-T2D trial in primary prevention. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk

Author

Arsenault, Benoit J., Petrides, Francine, Tabet, Fatiha, Bao, Weihang, Hovingh, G. Kees, Boekholdt, S. Matthijs, Ramin-Mangata, Stéphane, Meilhac, Olivier, DeMicco, David, Rye, Kerry-Anne, Waters, David D., Kastelein, John J.P., Barter, Philip, and Lambert, Gilles

Published
2018
Full Text
View/download PDF

17. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Author

Swerdlow, Daniel I, Preiss, David, Kuchenbaecker, Karoline B, Holmes, Michael V, Engmann, Jorgen E L, Shah, Tina, Sofat, Reecha, Stender, Stefan, Johnson, Paul C D, Scott, Robert A, Leusink, Maarten, Verweij, Niek, Sharp, Stephen J, Guo, Yiran, Giambartolomei, Claudia, Chung, Christina, Peasey, Anne, Amuzu, Antoinette, Li, KaWah, Palmen, Jutta, Howard, Philip, Cooper, Jackie A, Drenos, Fotios, Li, Yun R, Lowe, Gordon, Gallacher, John, Stewart, Marlene C W, Tzoulaki, Ioanna, Buxbaum, Sarah G, van der A, Daphne L, Forouhi, Nita G, Onland-Moret, N Charlotte, van der Schouw, Yvonne T, Schnabel, Renate B, Hubacek, Jaroslav A, Kubinova, Ruzena, Baceviciene, Migle, Tamosiunas, Abdonas, Pajak, Andrzej, Topor-Madry, Romanvan, Stepaniak, Urszula, Malyutina, Sofia, Baldassarre, Damiano, Sennblad, Bengt, Tremoli, Elena, de Faire, Ulf, Veglia, Fabrizio, Ford, Ian, Jukema, J Wouter, Westendorp, Rudi G J, de Borst, Gert Jan, de Jong, Pim A, Algra, Ale, Spiering, Wilko, der Zee, Anke H Maitland-van, Klungel, Olaf H, de Boer, Anthonius, Doevendans, Pieter A, Eaton, Charles B, Robinson, Jennifer G, Duggan, David, Kjekshus, John, Downs, John R, Gotto, Antonio M, Keech, Anthony C, Marchioli, Roberto, Tognoni, Gianni, Sever, Peter S, Poulter, Neil R, Waters, David D, Pedersen, Terje R, Amarenco, Pierre, Nakamura, Haruo, McMurray, John J V, Lewsey, James D, Chasman, Daniel I, Ridker, Paul M, Maggioni, Aldo P, Tavazzi, Luigi, Ray, Kausik K, Seshasai, Sreenivasa Rao Kondapally, Manson, JoAnn E, Price, Jackie F, Whincup, Peter H, Morris, Richard W, Lawlor, Debbie A, Smith, George Davey, Ben-Shlomo, Yoav, Schreiner, Pamela J, Fornage, Myriam, Siscovick, David S, Cushman, Mary, Kumari, Meena, Wareham, Nick J, Verschuren, W M Monique, Redline, Susan, Patel, Sanjay R, Whittaker, John C, Hamsten, Anders, Delaney, Joseph A, Dale, Caroline, Gaunt, Tom R, Wong, Andrew, Kuh, Diana, Hardy, Rebecca, Kathiresan, Sekar, Castillo, Berta A, van der Harst, Pim, Brunner, Eric J, Tybjaerg-Hansen, Anne, Marmot, Michael G, Krauss, Ronald M, Tsai, Michael, Coresh, Josef, Hoogeveen, Ronald C, Psaty, Bruce M, Lange, Leslie A, Hakonarson, Hakon, Dudbridge, Frank, Humphries, Steve E, Talmud, Philippa J, Kivimäki, Mika, Timpson, Nicholas J, Langenberg, Claudia, Asselbergs, Folkert W, Voevoda, Mikhail, Bobak, Martin, Pikhart, Hynek, Wilson, James G, Reiner, Alex P, Keating, Brendan J, Hingorani, Aroon D, and Sattar, Naveed

Published
2015
Full Text
View/download PDF

18. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial

Author

Tardif, Jean Claude, Pfeffer, Marc A., Kouz, Simon, Koenig, Wolfgang, Maggioni, Aldo P., McMurray, John J. V., Mooser, Vincent, Waters, David D., Grégoire, Jean C., L’Allier, Philippe L., Jukema, Wouter J., White, Harvey D., Heinonen, Therese, Black, Donald M., Laghrissi-Thode, Fouzia, Levesque, Sylvie, Guertin, Marie Claude, and Dubé, Marie Pierre

Abstract

Aims:\ud In a retrospective analysis of dal-Outcomes, the effect of dalcetrapib on cardiovascular events was influenced by an adenylate cyclase type 9 (ADCY9) gene polymorphism. The dal-GenE study was conducted to test this pharmacogenetic hypothesis.\ud \ud Methods and results:\ud dal-GenE was a double-blind trial in patients with an acute coronary syndrome within 1–3 months and the AA genotype at variant rs1967309 in the ADCY9 gene. A total of 6147 patients were randomly assigned to receive dalcetrapib 600 mg or placebo daily. The primary endpoint was the time from randomization to first occurrence of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke. After a median follow-up of 39.9 months, the primary endpoint occurred in 292 (9.5%) of 3071 patients in the dalcetrapib group and 327 (10.6%) of 3076 patients in the placebo group [hazard ratio 0.88; 95% confidence interval (CI) 0.75–1.03; P = 0.12]. The hazard ratios for the components of the primary endpoint were 0.79 (95% CI 0.65–0.96) for myocardial infarction, 0.92 (95% CI 0.64–1.33) for stroke, 1.21 (95% CI 0.91–1.60) for death from cardiovascular causes, and 2.33 (95% CI 0.60–9.02) for resuscitated cardiac arrest. In a pre-specified on-treatment sensitivity analysis, the primary endpoint event rate was 7.8% (236/3015) in the dalcetrapib group and 9.3% (282/3031) in the placebo group (hazard ratio 0.83; 95% CI 0.70–0.98).\ud \ud Conclusion:\ud Dalcetrapib did not significantly reduce the risk of occurrence of the primary endpoint of ischaemic cardiovascular events at end of study. A new trial would be needed to test the pharmacogenetic hypothesis that dalcetrapib improves the prognosis of patients with the AA genotype.

Published
2022

36. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

Author

Preiss, David, Campbell, Ross T., Murray, Heather M., Ford, Ian, Packard, Chris J., Sattar, Naveed, Rahimi, Kazem, Colhoun, Helen M., Waters, David D., LaRosa, John C., Amarenco, Pierre, Pedersen, Terje R., Tikkanen, Matti J., Koren, Michael J., Poulter, Neil R., Sever, Peter S., Ridker, Paul M., MacFadyen, Jean G., Solomon, Scott D., Davis, Barry R., Simpson, Lara M., Nakamura, Haruo, Mizuno, Kyoichi, Marfisi, Rosa M., Marchioli, Roberto, Tognoni, Gianni, Athyros, Vasilios G., Ray, Kausik K., Gotto, Antonio M., Clearfield, Michael B., Downs, John R., and McMurray, John J.

Published
2015
Full Text
View/download PDF

41. Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

Author

Faergeman, Ole, Holme, Ingar, Fayyad, Rana, Bhatia, Sonal, Grundy, Scott M., Kastelein, John J.P., LaRosa, John C., Larsen, Mogens Lytken, Lindahl, Christina, Olsson, Anders G., Tikkanen, Matti J., Waters, David D., and Pedersen, Terje R.

Published
2009
Full Text
View/download PDF

42. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Author

Tardif, Jean-Claude Bouabdallaoui, Nadia L'Allier, Philippe L. and Gaudet, Daniel Shah, Binita Pillinger, Michael H. and Lopez-Sendon, Jose da Luz, Protasio Verret, Lucie Audet, Sylvia Dupuis, Jocelyn Denault, Andre Pelletier, Martin and Tessier, Philippe A. Samson, Sarah Fortin, Denis Tardif, Jean-Daniel Busseuil, David Goulet, Elisabeth Lacoste, Chantal Dubois, Anick Joshi, Avni Y. Waters, David D. and Hsue, Priscilla Lepor, Norman E. Lesage, Frederic Sainturet, Nicolas Roy-Clavel, Eve Bassevitch, Zohar Orfanos, Andreas and Stamatescu, Gabriela Gregoire, Jean C. Busque, Lambert and Lavallee, Christian Hetu, Pierre-Olivier Paquette, Jean-Sebastien Deftereos, Spyridon G. Levesque, Sylvie and Cossette, Marieve Nozza, Anna Chabot-Blanchet, Malorie Dube, Marie-Pierre Guertin, Marie-Claude Boivin, Guy COLCORONA Investigators

Abstract

Background Evidence suggests a role for excessive inflammation in COVID-19 complications. Colchicine is an oral anti-inflammatory medication beneficial in gout, pericarditis, and coronary disease. We aimed to investigate the effect of colchicine on the composite of COVID-19-related death or hospital admission. Methods The present study is a phase 3, randomised, double-blind, adaptive, placebo-controlled, multicentre trial. The study was done in Brazil, Canada, Greece, South Africa, Spain, and the USA, and was led by the Montreal Heart Institute. Patients with COVID-19 diagnosed by PCR testing or clinical criteria who were not being treated in hospital were eligible if they were at least 40 years old and had at least one high-risk characteristic. The randomisation list was computer-generated by an unmasked biostatistician, and masked randomisation was centralised and done electronically through an automated interactive web-response system. The allocation sequence was unstratified and used a 1:1 ratio with a blocking schema and block sizes of six. Patients were randomly assigned to receive orally administered colchicine (0middot5 mg twice per day for 3 days and then once per day for 27 days thereafter) or matching placebo. The primary efficacy endpoint was the composite of death or hospital admission for COVID-19. Vital status at the end of the study was available for 97middot9% of patients. The analyses were done according to the intention-to-treat principle. The COLCORONA trial is registered with ClinicalTrials.gov (NCT04322682) and is now closed to new participants. Findings Trial enrolment began in March 23, 2020, and was completed in Dec 22, 2020. A total of 4488 patients (53middot9% women; median age 54middot0 years, IQR 47middot0-61middot0) were enrolled and 2235 patients were randomly assigned to colchicine and 2253 to placebo. The primary endpoint occurred in 104 (4middot7%) of 2235 patients in the colchicine group and 131 (5middot8%) of 2253 patients in the placebo group (odds ratio [OR] 0middot79, 95middot1% CI 0middot61-1middot03; p=0middot081). Among the 4159 patients with PCR-confirmed COVID-19, the primary endpoint occurred in 96 (4middot6%) of 2075 patients in the colchicine group and 126 (6middot0%) of 2084 patients in the placebo group (OR 0middot75, 0middot57-0middot99; p=0middot042). Serious adverse events were reported in 108 (4middot9%) of 2195 patients in the colchicine group and 139 (6middot3%) of 2217 patients in the placebo group (p=0middot051); pneumonia occurred in 63 (2middot9%) of 2195 patients in the colchicine group and 92 (4middot1%) of 2217 patients in the placebo group (p=0middot021). Diarrhoea was reported in 300 (13middot7%) of 2195 patients in the colchicine group and 161 (7middot3%) of 2217 patients in the placebo group (p

Published
2021

43. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial†

Author

Tardif, Jean-Claude, Ballantyne, Christie M., Barter, Philip, Dasseux, Jean-Louis, Fayad, Zahi A., Guertin, Marie-Claude, Kastelein, John J. P., Keyserling, Constance, Klepp, Heather, Koenig, Wolfgang, LʼAllier, Philippe L., Lespérance, Jacques, Lüscher, Thomas F., Paolini, John F., Tawakol, Ahmed, Waters, David D., Pfeffer, M., Brown, V., Rouleau, J., Watkins, P., Wei, L.J., Gosselin, G., Chayer, C., Lanthier, S., Pelletier, G.B., Racine, N., Agarwal, H., Brilakis, E., Cannon, L., Carrié, D., Corbelli, J., Coste, P., de Winter, R., Diaz, A., Eisenberg, S., Ennis, B., Fajadet, J., Fam, N., Fortuin, D., Gessler, C., Grines, C., Guerra, D., Gum, H., Haldis, T., Heestermans, T., Herrman, J.P., Huynh, T., Kedhi, E., Koren, M., Kouz, S., Krolick, M., Kumkumian, G., Lavi, S., Li, R.J., Masud, ARZ, McAlhany, C., McGrew, F.A., OʼShaughnessy, C., Oude Ophuis, A.J.M., Parr, K., Penny, W., Pesant, Y., Post, H., Robinson, S., Rodes-Cabau, J., Roy, A., Schulman, S., Spence, F., Stouffer, G., Stys, T., Sussex, B., Tahirkheli, N., Tardif, J-C., Grégoire, J., ten Berg, J., van Boven, A.J., von Birgelen, C., and Weinstein, D.

Published
2014
Full Text
View/download PDF

49. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A.sub.2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

Author

Rosenson, Robert S., Hislop, Colin, McConnell, Daniel, Elliott, Michael, Stasiv, Yuri, Wang, Nan, and Waters, David D.

Subjects
Phospholipases -- Physiological aspects, Atherosclerosis -- Risk factors, Atherosclerosis -- Development and progression, Blood lipoproteins -- Physiological aspects, Lipoproteins -- Physiological aspects, Proteolipids -- Physiological aspects, Coronary heart disease -- Physiological aspects
Published
2009

50. Effects of torcetrapid in patients at high risk for coronary events

Author

Barter, Philip J., Caulfield, Mark, Eriksson, Mats, Grundy, Scott M., Kastelein, John J.P., Komajda, Michel, Lopez-Sendon, Jose, Mosca, Lori, Tardif, Jean-Claude, Waters, David D., Shear, Charles L., Revkin, James H., Buhr, Kevin A., Risher, Marian R., Tall, Alan R., and Brewer, Bryan

Subjects
Torcetrapib (Medication) -- Research, Torcetrapib (Medication) -- Complications and side effects, Anticholesteremic agents -- Research, Anticholesteremic agents -- Complications and side effects, Heart -- Abnormalities, Heart -- Risk factors
Abstract

A randomized, double-blind trial was conducted to determine efficacy of torcetrapib, a potent cholesteryl ester transfer protein inhibitor to reduce major cardiovascular events. The trial was terminated prematurely as it increased risk of death and cardiac events in patients receiving torcetrapib.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results